

A Meeting of the Nutrition Society, hosted by the Irish Section, was held at the O'Reilly Hall, University College Dublin, Dublin, Republic of Ireland on 18–20 June 2008

Symposium on 'The challenge of translating nutrition research into public health nutrition'

Session 1: Public health nutrition Folic acid food fortification: the Irish experience

Mary A. T. Flynn*, Wayne A. Anderson, Sarah J. Burke and Alan Reilly
Food Safety Authority of Ireland, Abbey Court, Lower Abbey Street, Dublin 1, Republic of Ireland

Adequate intake of folic acid by women during very early pregnancy can markedly reduce risk of the development of neural-tube defects (NTD). The effectiveness of advice to women to take folic acid supplements is limited, mainly because 50% of pregnancies are unplanned. However, mandatory folic acid food fortification programmes in North America have been very successful in reducing NTD rates. In Ireland higher rates of pregnancies are affected by NTD and the option of termination is illegal. Consequently, the much higher burden of disease makes primary prevention of NTD an important public health issue in Ireland. During 2006 a decision was taken in Ireland to initiate mandatory folic acid fortification of most bread to prevent NTD. Priority work was immediately undertaken to establish reliable and comprehensive baseline information on factors that will be affected by fortification. This information included data on: the national prevalence of pregnancies affected by NTD; the current extent of voluntary folic acid fortification of food on the Irish market and how it affects folic acid intakes; blood folate status indicators assessed for various subgroups of the Irish population. In addition, scientific developments that have arisen since 2006 relating to the risks and benefits of folic acid intake are under ongoing review. The present paper summarises the rationale for mandatory folic acid food fortification in Ireland and recent scientific developments relating to risks and benefits of folic acid intake. In this context, preliminary findings of baseline monitoring investigations in Ireland are considered.

Folic acid: Food fortification: Public health risk and benefit

Rationale for a mandatory folic acid food fortification programme in Ireland

Since 1991 it has been known that $\leq 70\%$ of neural-tube defects (NTD) can be prevented by the consumption of folic acid before and at the time of conception⁽¹⁾. From the mid 1990s Ireland, in common with many other developed countries, had a policy of advising women of child-bearing age to take folic acid supplements. However, experience has shown that this policy has only had a marginal impact on NTD rates in Ireland and elsewhere⁽²⁾. This outcome is mainly the result of:

1. the impromptu nature of pregnancy. Despite advances in contraception less than half all pregnancies are

- planned in Ireland; a rate that is comparable with other developed countries;
2. it is only in the very early stages of pregnancy that folic acid can be protective. Taking folic acid when pregnancy is suspected is generally too late to prevent NTD because the neural tube is completely developed 21–28 d post conception.

As a result of this situation mandatory folic acid fortification of cereal grains and flour was introduced in North America in 1998. Research has shown that such food fortification has resulted in a 20–70% reduction in rates of pregnancies affected by NTD^(3–5).

By 2006 all available evidence had indicated that a mandatory folic acid food fortification programme would

Abbreviations: NTD, neural-tube defects; RCF, erythrocyte folate.

***Corresponding author:** Dr Mary Flynn, fax +3531 8171 301, email mflynn@fsai.ie

contribute substantially to a reduction in the numbers of babies born with NTD in Ireland⁽⁶⁾. For >30 years Ireland had been recognised as having one of the highest rates of pregnancies affected by NTD in the world⁽²⁾. The cause of this particular vulnerability to the development of NTD in Ireland has a genetic basis. Recent studies have shown that approximately 50% of the Irish population have variations in the gene coding for an enzyme involved in folate metabolism, 5,10-methylenetetrahydrofolate reductase^(7–9). Such genetic variations may account for ≤26% of NTD-affected births in Ireland⁽¹⁰⁾. The situation in other countries is different in that the overall incidence of NTD is lower and most of the affected pregnancies are terminated. Termination of pregnancy is illegal in Ireland and as a consequence Ireland bears a much higher burden of disease. Research carried out by the Health Research Board shows that the percentage of pregnancies affected by NTD that are delivered as live births is much higher in Dublin (81) compared with other centres (e.g. Paris, France 11 and North Thames, UK 13; PN Kirke, personal communication). This position places a greater onus on Ireland to maximise the primary prevention of these serious birth defects.

In July 2006 the Minister for Health and Children in Ireland accepted the recommendation of the National Committee on Folic Acid Food Fortification to introduce a mandatory folic acid fortification programme that would ensure that most bread in Ireland would be fortified⁽⁶⁾. The level of folic acid fortification of bread proposed for Ireland (120 µg/100 g bread) would deliver a similar amount of folic acid to women of child-bearing age to that provided to North American women through their mandatory fortification of flour. At the request of the Department of Health and Children the Food Safety Authority of Ireland has led an expert working group to carry out the preparatory work involved in implementing the fortification programme.

Priorities in preparatory work pre-fortification

One of the key lessons learned during the implementation of national folic acid food fortification programmes in the USA and Canada concerns the need for a comprehensive evaluation plan to monitor the effectiveness and safety of the fortification intervention⁽¹¹⁾. It was recognised that available data in Ireland needed to be up-dated to ensure an accurate pre-fortification assessment of all factors that would be affected by mandatory folic acid fortification⁽⁶⁾.

Immediate action was taken to establish comprehensive reliable baseline information on important indicators against which the future effects of mandatory folic acid fortification of most bread in Ireland could be measured. These indicators include:

1. accurate information on the numbers of pregnancies affected by NTD;
2. assessment of the current extent of voluntary folic acid fortification of food on the Irish market and how it affects folic acid intakes;
3. analysis of the current level of voluntary folic acid fortification of bread marketed in Ireland;

4. information on the blood folate status of population subgroups in Ireland.

Preliminary findings from these investigations are discussed later in terms of scientific developments relative to the risk and benefits of folic acid food fortification.

Evaluation of scientific developments relevant to folic acid fortification

Scientific developments relevant to folic acid food fortification are being continuously monitored by the Food Safety Authority of Ireland. Research activity in three areas has come under review in terms of ongoing assessment of the risks and benefits of folic acid food fortification, i.e. cognitive function in older adults, CVD and cancer.

Cognitive function

Cognitive function declines with age, especially cognitive domains related to memory and information processing speed. Folic acid consumption, with or without vitamin B₁₂, may help prevent cognitive impairment in the elderly, possibly through lowering plasma homocysteine levels^(12,13). A 3-year randomised double-blind placebo-controlled trial involving >800 older adults (aged 50–70 years, all vitamin B₁₂ replete) in The Netherlands has found that supplements of 800 µg folic acid over 3 years improve cognitive function⁽¹⁴⁾. Improvements in this trial were found to involve domains of cognitive function associated with ageing and these changes were shown to be associated with reductions in homocysteine⁽¹⁴⁾. In a previous similar trial (2-year randomised double-blind placebo-controlled trial in New Zealand involving >276 older adults (≥65 years) with elevated homocysteine levels (≥13 µmol/l) using high-dose supplements of folic acid (1000 µg), vitamin B₁₂ (500 µg) and vitamin B₆ (10 mg) as the homocysteine-lowering intervention) no beneficial effects of homocysteine-lowering on cognition were found⁽¹⁵⁾. The lack of effect found in this earlier trial has been partly attributed to the less-sensitive test used to assess cognitive function (mini-mental state examination) in the New Zealand trial⁽¹⁵⁾ v. five separate tests of different cognitive domains used in the Dutch trial⁽¹⁴⁾. However, a recent analysis of the relationship between blood levels of folate and vitamin B₁₂ in older adult participants (>60 years, *n* 1459) in the 1999–2002 US National Health and Nutrition Examination Survey and measures of cognitive function has found that the protective effects of folate on cognitive function are dependent on adequate vitamin B₁₂ status⁽¹⁶⁾. This study suggests that if vitamin B₁₂ status is adequate, then folic acid (even at high intake levels) seems to be protective of cognitive function^(16,17). However, if vitamin B₁₂ status is not adequate, the associated cognitive impairment seems to be made worse by high intakes of folic acid^(16,17). These divergent effects of folic acid intake depending on vitamin B₁₂ status need to be confirmed. The two randomised controlled trials described earlier^(14,15) cannot contribute to this evidence because either a high dose of vitamin B₁₂ was administered with

folic acid⁽¹⁵⁾ or the trial only included individuals who were vitamin B₁₂ replete⁽¹⁴⁾.

Collectively, these recent reports indicate a beneficial effect of folic acid food fortification on cognitive function of older adults, but this effect may be dependent on adequate vitamin B₁₂ status. Thus, the main implication for folic acid food fortification is to emphasise the importance of ensuring older adults with low vitamin B₁₂ status are identified and treated.

CVD

Folic acid food fortification is associated with a reduced risk of stroke^(18–20). While observational data indicate that low folate intake levels are a risk factor for CVD, the evidence from trials is not consistent. Trials carried out to date have been underpowered and so definitive evidence on the possible protective effects against CHD require meta-analysis of the results of recent and ongoing trials^(21–23). The results of such meta-analysis are expected to become available in early 2009.

Cancer

For some time folate has been considered to have a role in cancer prevention. Folate deficiency has been linked to the risk of cancer in human subjects, including cancer of the colon, other parts of the gastrointestinal tract, pancreas and breast (for review, see Kim⁽²⁴⁾). Some, but not all, retrospective studies suggest higher dietary intake levels and higher blood markers of folate status are generally associated with a reduced risk of malignant disease, especially involving the colo-rectum^(24–26). As a result of these disparate findings a definitive study was undertaken to test the chemopreventive effect of folate on colo-rectal adenomas or polyps (well-established precursors of colo-rectal cancer). This 6-year randomised controlled trial involving individuals with a recent history of these lesions has found that supplementation with a high dose of folic acid (1 mg/d) does not prevent the recurrence of adenomas. Conversely, this study has demonstrated at second follow-up that high-dose folic acid supplementation is associated with a 67% increased risk of advanced lesions (risk ratio 1.67 (95% CI 1.00, 2.80); $P = 0.05$), along with a >2-fold increased risk of having at least three adenomas (risk ratio 2.32 (95% CI 1.23, 4.35); $P = 0.02$)⁽²⁷⁾. The publication of this study provides support for the theory (arising from animal studies) that folate (folic acid) nutrition may have a dual role in the development of cancer, i.e. a harmful role in addition to the protective role that is well documented in previous studies.

In addition, a recent epidemiological study of time trends for colo-rectal cancer incidence in the USA and Canada speculates that the introduction of folic acid fortification may have been responsible for an observed increase in colo-rectal cancer incidence⁽²⁸⁾. This study shows that mandatory fortification of foods with folic acid occurred at about the same time as non-significant increases in colo-rectal cancer incidence⁽²⁸⁾. However, it has been noted that if the increased rate of colo-rectal cancer was caused by folic acid fortification, the effect of folic

acid on progression of cancer would have had to occur immediately⁽²⁹⁾. Furthermore, the timing of increases in the blood folate status of the American population is also not clearly consistent with changes in colo-rectal cancer incidence outlined in the time trends report⁽²⁸⁾.

While developments relating to folic acid food fortification in CVD and cognitive function of older adults do not appear to be of major concern, the emerging issues in cancer risk are important. Increased risk of colo-rectal cancer precursors reported in the folate-supplementation trial⁽²⁷⁾ are associated with folic acid intakes in excess of the upper safe level of 1 mg/d⁽³⁰⁾, which is many times higher than the increase in folic acid intake that would be delivered by mandatory fortification in Ireland.

The outcome of the folate-supplementation trial⁽²⁷⁾ raises concerns and many questions, including uncertainty about what constitutes a safe level of folic acid intake and what factors influence this safe level.

Folic acid and the development of cancer

Role of folate in DNA replication and repair

Folate and other B-vitamins (vitamins B₆ and B₁₂) function as coenzymes in C₁ metabolism, which is critical for the synthesis and methylation of DNA⁽³¹⁾. Folate is required for the conversion of homocysteine into methionine and eventually into *S*-adenosylmethionine, which is the primary donor of methyl groups for most methylation reactions, including DNA methylation⁽³¹⁾. Folate also assists in the synthesis of purines and thymidylate for DNA synthesis⁽³¹⁾. DNA methylation is central to gene silencing and, potentially, to the suppression of repetitive DNA of viral origin^(25,32). Deficiency of folate, or the other B-vitamins involved in these C₁ reactions, may interfere with DNA methylation and synthesis, leading to aberrant gene expression and DNA instability and the eventual development of birth defects and cancer^(24,33,34). However, the precise influence of folate status on DNA methylation is not well defined; thus, the effects of folate status on cell biology are unclear⁽²⁵⁾.

Dual role of folate in cancer development: the importance of timing

Despite the central function of folate in maintaining DNA integrity and stability, folate nutrition may have dual effects on cancer development^(24–26). Several lines of experimental data (studies involving animals and cell cultures) indicate that both the timing and dose of folate supplementation during carcinogenesis are important^(25,26,35,36). Although increases in folic acid intake before the existence of pre-cancerous lesions (such as adenomas or microscopic adenomas) can prevent tumour development, once pre-cancerous lesions are present supplementation with folic acid may increase tumour growth⁽²⁵⁾. This potential for a dual modulatory role for folate on carcinogenesis has been outlined⁽²⁴⁾ as follows:

1. cancer prevention: studies of cell biology and studies involving animals provide strong evidence that folate adequacy is protective against cancer through the

central role it plays in DNA function and repair. Such studies indicate that where there is folate deficiency, DNA repair and function is upset. The resulting abnormal patterns in DNA function are among the most common identified in the development of cancer;

2. cancer promotion: cancer cells have much higher rates of growth and replication compared with normal healthy cells. These higher growth rates require accelerated DNA synthesis. Thus, the key role that folate plays in DNA synthesis and replication makes folate a potential growth promoter of cancerous cells. Studies of cell biology have shown that cancer cells tend to increase their uptake of folate, which explains why chemical agents that have an anti-folate effect are the basis for chemotherapy for cancer^(37,38).

Folic acid and cancer: importance of the amount and form of folate consumed

Two recent studies of post-menopausal breast cancer risk and folate nutrition highlight the importance of the amount of folate consumed in determining safety or risk^(25,39,40). In 2006 the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial in America involving 25 400 women (aged ≥ 55 years) reported that very high folate intakes, attributed to excessive supplement use (folic acid $\geq 400 \mu\text{g}/\text{d}$), may generally be harmful rather than beneficial in breast-cancer development compared with taking no folic acid supplements (adjusted hazard ratio 1.19 (95% CI 1.01, 1.41); $P = 0.04$)⁽⁴⁰⁾. Conversely, in a more recent report from the Swedish Malmo Diet and Cancer study (cohort of 11 699 women, aged ≥ 50 years) women with the highest folate intakes were found to have $>40\%$ lower risk of breast cancer compared with women with the lowest folate intakes⁽³⁹⁾. Differences in the amount of folate consumed among these two cohorts of women (mean daily folate intake among women in the highest quintile of intake was $853 \mu\text{g}$ in the American cohort⁽⁴⁰⁾ v. $349 \mu\text{g}$ in the Swedish cohort⁽³⁹⁾) may explain the divergent outcomes in breast cancer risk associated with folate intake⁽²⁶⁾.

However, the form of folate may also explain the different outcomes in these two studies. In the American study increased breast cancer risk was found to be associated with high dose ($\geq 400 \mu\text{g}/\text{d}$) folic acid supplements⁽⁴⁰⁾, while in the Swedish study beneficial effects were found to be associated with total dietary folate intake, i.e. natural folate and folic acid from supplements⁽³⁹⁾. Since only 19% of the Swedish women took folic acid supplements⁽³⁹⁾, the beneficial effects relating to folate intake could be associated with the natural form of the vitamin folate v. the synthetic form folic acid.

The bioavailability of folic acid (monoglutamic form) is much greater than that of natural folate (polyglutamate form). Usually once folic acid is absorbed it is converted to 5-methyltetrahydrofolate and metabolised as natural folate⁽³¹⁾. However, if large doses of folic acid are consumed the mechanisms converting monoglutamates to 5-methyltetrahydrofolate are saturated and 'free' (unmetabolised) folic acid appears in plasma⁽⁴¹⁾, because the capacity for converting folic acid to 5-methyltetrahydrofolate in the small intestine is limited. If single doses of




Fig. 1. Folic acid intake and cancer risk. Increased cancer risk is evident at the extremes of deficient and excessive intake levels; however, the criteria defining these extremes are unknown.

folic acid exceed $200 \mu\text{g}$, they are not metabolised immediately, resulting in 'free' folic acid circulating in the blood⁽⁴¹⁾; a phenomenon not encountered from consumption of natural folates. Unlike 5-methyltetrahydrofolate, 'free' folic acid does not require activation to become involved in DNA synthesis. In a situation in which fast-growing cancer cells require accelerated DNA synthesis the potential of 'free' folic acid as a growth promoter of cancerous cells is obvious.

Gene–nutrient interactions

There is a growing body of evidence to link differential cancer risks with the polymorphisms in the folate metabolic pathway (methylene tetrahydrofolate reductase C677T and A1298C). In the case of colo-rectal cancer some research indicates that the two polymorphisms might protect against colo-rectal adenomas developing into cancer⁽⁴²⁾, while other research indicates differential vulnerability to type of colo-rectal tumour^(43,44).

Folic acid and the development of cancer: summary

The recent data linking folic acid intakes with cancer risk emphasise the importance of ensuring a safe level of folic acid intake across all subgroups of the population. There are many examples in nutritional science to indicate that risk of adverse effects generally occur at the extremes of nutrient intake (e.g. vitamin A, vitamin D, polyunsaturated fats)^(30,45,46). Considering the evidence discussed earlier, this relationship would also seem to apply to folic acid and the development of cancer, as risk is increased in both folate deficiency and overload (see Fig. 1). In the absence of any folic acid intake, folate deficiency can affect between 5 and 16% of the population, leaving them vulnerable to both NTD and cancer. The big problem is that the optimal level of folic acid intake in relation to cancer risk remains unknown (see Fig. 1). As folate status is partly determined by the genetic characteristics of the




Fig. 2. Neonatal outcome of pregnancies affected by neural-tube defects in Ireland in 2005–7 (S Daly, unpublished results).

population⁽⁷⁾ optimal intake is likely to be influenced by genetic make-up.

Folic acid food fortification: the Irish experience

As outlined earlier, preparatory work for implementation of the mandatory folic acid fortification programme has involved prioritising research to establish reliable baseline indicators of pre-fortification status in Ireland. The remainder of the paper considers the preliminary findings of this research in the context of the scientific developments on risks and benefits associated with folic acid intake.

Pregnancies affected by neural-tube defects in Ireland

The establishment of a national register of congenital birth defects is a long-term process. Thus, for the purposes of getting reliable pre-fortification data on the incidence of pregnancies affected by NTD in Ireland, a special audit of cases occurring from 2005 to 2007 was undertaken. Data on prenatal ultrasound scans and birth records from the twenty-one obstetric units in Ireland was used to estimate prevalence rate for pregnancies affected by NTD. This method is much more complete than previous estimations in Ireland because national coverage was provided and information on all affected pregnancies, including those that do not reach term, was counted. The neonatal outcome of affected pregnancies during this period is shown in Fig. 2, which shows 26% did not reach term and, as such, were unaccounted for in previous reports (S Daly, unpublished results). Despite including these cases, the overall estimation of pregnancies affected by NTD during 2005–7 is lower than previous estimates; preliminary data indicates a rate of 0.92 cases per 1000 pregnancies during 2005–7 *v.* 1.0–1.3 cases (without including cases not reaching term) per 1000 cases during 1997–2001 (S Daly, unpublished results).

Table 1. Voluntary folic acid fortification of food; food categories, fortification levels and market share of fortified foods on Irish market in August 2007 (data from McMenamin *et al.*⁽⁴⁷⁾)

Food category	No. of brands	Declared folic acid fortification levels ($\mu\text{g}/100\text{g}$)	Percentage of the category market held by fortified products†
Breakfast cereal	104	110–571	60
Cereal bars	27	100–250	29
Fat spreads*	15	100–1000	16
Milk	4	30–70	5
Juice	11	0.07–100	5
Dried soup	4	18–30	13
Yoghurt	2	40–200	1
White bread	38†	30–300†	6
Brown bread			2
Wholemeal bread			17

*Follow-up checks in May 2008 identified 50% less folic acid in several brands of fortified fat spreads (August 2007 fortified at 1000 $\mu\text{g}/100\text{g}$ and in May 2008 fortified at 500 $\mu\text{g}/100\text{g}$).

†Data for the three types of bread.

‡Based on volume sales 2007 (data supplied by TNS, Blackrock, Co. Dublin, Republic of Ireland).

Voluntary folic acid food fortification

Folic acid-fortified foods on the Irish market and their impact on folic acid intakes

Surveys of the major supermarket outlets in the Dublin area during the summer of 2007 have identified 211 foods on the Irish market that are voluntarily fortified with folic acid. A summary of food categories fortified, range of fortification levels and market share of fortified products are given in Table 1⁽⁴⁷⁾. These data show that the range of foods voluntarily fortified with folic acid is extensive and the amounts of folic acid added (according to nutrient content declarations on food labels) between brands is very variable (e.g. fat spreads). This variability is also evident within brands (e.g. different breakfast cereals of the same brand providing 166 μg folic acid/100 g cereal *v.* 334 μg folic acid/100 g cereal).

The 1999 national survey database of adult food intake has been updated to reflect 2007 levels of voluntary folic acid fortification of food. Probabilistic modelling indicates that folic acid intakes of women aged 18–50 years (target group) based on 2007 compared with 1999 food fortification patterns would be increased by approximately one-third (from 67 μg per individual per d to 90 μg per individual per d; Food Safety Authority of Ireland, unpublished results). While in 1999 more than one-third of women aged 18–50 years (35%; 130 of 369 women) did not consume any folic acid-fortified foods, updating the 1999 data in terms of 2007 folic acid food fortification estimates that this percentage of women would be reduced to <2 (seven of 369 women). Folic acid intakes of all adults in terms of the tolerable upper level for folic acid intake (1000 $\mu\text{g}/\text{d}$ ⁽³⁰⁾) reveal a substantial gap between the potential daily folic acid intakes of the highest folic acid consumers (99th percentile folic acid intakes) at 519 μg *v.* 1000 μg (Food Safety Authority of Ireland, unpublished results). The principal food categories responsible for the




Fig. 3. Difference between folic acid content declared on food labels and actual measured folic acid content of bread voluntarily fortified in Ireland during 2007.

increased estimates of folic acid intake in 2007 were fat spreads (particularly in older men) and bread products, which were not fortified in 1999⁽⁴⁷⁾ (Food Safety Authority of Ireland, unpublished results). It was not possible to update the food consumption database for changes in food supplement use, or content, and hence it is likely that folic acid exposure is underestimated in this analysis.

An analysis conducted on data from the National Food Consumption Survey of 5–12-year-old children ($n = 594$; data collected in 2003–4) living in Ireland has found that 10% ($n = 61$) had intakes in excess of the tolerable upper level for folic acid⁽⁴⁷⁾. Supplements made a major contribution to high intakes (100–400 μg in nineteen cases), followed by consumption of foods fortified with folic acid (mainly ready-to-eat breakfast cereals, followed by fortified milks, fortified juices and fortified fat spreads⁽⁴⁷⁾). The tolerable upper levels for folic acid intake in children (300 μg for 4–6 year olds; 400 μg for 7–10 year olds; 600 μg for 11–14 year olds) do not relate to adverse health risks but are derived from the tolerable upper level set for adults relating to risk of masking pernicious anaemia⁽³⁰⁾.

Voluntary folic acid fortification of bread in Ireland: analysis of actual content

Samples of all bread types marketed in Ireland (249 loaves of bread) have been analysed for folic acid content. Approximately one-fifth of bread brands were found to be fortified with folic acid and in general actual levels exceed declared levels. (One sample was found to contain 5096 μg folic acid/100 g bread and this sample was investigated separately. Investigations have revealed a systematic error in the quantity of folic acid added to the flour improver by the improver supplier allegedly following confusion over the agreed specification. This issue was resolved by the manufacturer and validated in subsequent testing by the Food Safety Authority of Ireland.) The difference between actual folic acid content and levels declared on food labels for those fifteen samples that made nutrient declarations is shown in Fig. 3; analysis reveals between 23 and 224% more folic acid than declared on food labels. This level of 'overage' is a matter of concern, particularly if it is evident for other voluntarily-fortified foods. These findings also indicate underestimation of dietary folic acid intakes from fortified foods because these intakes are generally assessed

in terms of the nutrient content declared on labels. Thus, actual folic acid intakes of population subgroups in Ireland may be greater than those indicated by dietary survey databases, including those updated in terms of current voluntary food fortification levels.

Achieving approximately 400 μg folic acid every day using fortified products

In the context of the recent associations between high folic acid intakes and cancer, women may be anxious to avoid excessive folic acid intakes (i.e. intakes $>400 \mu\text{g}/\text{d}$). Considering this issue, the ease of achieving 400 μg folic acid/d using fortified foods on the Irish market has been examined⁽⁴⁷⁾. Using the folic acid content declared on food labels, numerous daily options were easily devised and the wide range of folic acid-fortified foods available ensured individual food preferences were likely to be accommodated. However, the following challenges to such use of folic acid-fortified foods, in practice, were identified:

1. nutrition labelling in Europe is based on nutrient content/100 g or ml food product rather than an average serving. Estimation of folic acid intake from fortified foods therefore requires previous knowledge of average serving sizes and, in the context of everyday-life, reasonably complex calculations;
2. variability in amounts of folic acid added to different brands of the same food (e.g. bread in Table 1) or between similar foods within the same brand (e.g. cereals) makes it very difficult to become familiar with folic acid content of fortified foods;
3. the *ad hoc* nature of voluntary fortification, whereby levels of folic acid addition can be discontinued or radically changed, represent further difficulties (e.g. fat spreads in Table 1);
4. 'overage' resulting in higher amounts of folic acid in food products relative to the amounts declared on food labels.

Without revision of nutrition labelling regulations (e.g. in favour of using serving size, regulation of tolerance levels around nutrient content declared on labels) practical use of folic acid-fortified foods by women to achieve a daily intake of 400 μg folic acid is extremely difficult.

Table 2. Percentage of population subgroup cohorts in Ireland according to categories of erythrocyte folate (RCF) levels assessed during 2006 (JM Scott and AM Molloy unpublished results) and 1998⁽⁴⁸⁾

Categories of RCF levels (ng/ml)	Status	2006				1998
		Men ≥65 years (n 292)	All women ≥65 years (n 495)	Women 16–40 years (n 259)	Children <16 years (n 218)	Girls 14–17 years (n 305)
≤ 150	Deficient	0	1.2	1	0.5	5
151–200	Possible deficiency	1.3	3.8	5	1.8	70
201–400	Low–adequate	33.6	41.2	41	27.5	
401–1000	Adequate–high	64.4	50.9	51	66.5	25
>1000	High	0.7	2.8	1	3.7	

Table 3. Percentage of population subgroup cohorts in Ireland according to categories of serum folate levels assessed during 2006 and 2007 (JM Scott and AM Molloy, unpublished results)

Categories of serum folate (ng/l)	Status	Children <16 years (n 220)	Women 16–40 years (n 259)	All women ≤65 years (n 496)	Men ≤65 years (n 292)	Older adults 65–95 years (n 462)
≤ 2	Deficient	0.9	1.5	1.4	1.7	0.7
2–3	Possible deficiency	1.4	5.4	5.6	11.6	1.8
3–10	Low–adequate	34.1	54	51.6	63.4	31.5
10–20	Adequate–high	39.1	32	32.7	20.9	31.7
>20	High	24.5	6.9	8.7	2.4	34.3

Blood folate status of population sub-groups in Ireland

Factors such as 'overage' (nutrient fortification above level declared), increasing voluntary folic acid food fortification, difficulties in assessing specific food brand intake and underreporting actual food intake collectively suggest that Irish dietary intake data may have under-represented true folic acid intake levels. Biochemical indicators of folate status therefore provide critical assessment of actual exposure to folic acid in the food supply. Erythrocyte folate (RCF) and serum folate have been determined in blood samples of particular subgroups of the Irish population collected during 2006. The population subgroups were purposely recruited to represent age and gender groups of interest and included children <16 years (*n* 230; 50% female), women of child-bearing age (*n* 259; 16–40 years) and middle-aged women (*n* 292; aged 40–60 years), adult men (*n* 292) and older adults >65 years (*n* 462; 55% female). Data on multivitamin supplement use were also recorded.

Reflective of the recent proliferation of folic acid-fortified foods on the Irish market, RCF and serum folate levels from samples collected in 2006 generally point to a high folate status, as shown in Tables 2 and 3. Compared with earlier reports from the same laboratory in 1998 showing that 5% of adolescent girls were folate deficient (RCF <150 ng/ml)⁽⁴⁸⁾, very few (approximately 1%) individuals were found to be folate deficient in 2006. Previously, RCF levels >400 ng/ml in women have been shown to be protective against the development of NTD⁽⁴⁹⁾. Samples collected from women of child-bearing age (16–40 years) in 2006, compared with those collected from teenage girls in 1998, indicate that the percentage of

women with a RCF status >400 ng/ml has more than doubled in Ireland over recent years (53 in 2006 *v.* 25 in 1998; Table 2). Dietary intake data in the 1998 study show that folic acid-fortified foods (breakfast cereals, milk and bread) contributed significantly to the variance in RCF levels found among the teenage girls⁽⁴⁸⁾.

High RCF levels (>1000 ng/ml) are evident in 3–4% of women and children, as compared with <1% of adult men. No RCF data are available for older adults in 2006. However, as shown in Table 3, high serum folate levels are evident in more than one-third (34%) of elderly individuals, and one-quarter (24.5%) of children, compared with 2% of men and <9% of women. All blood samples were collected from non-fasting participants and therefore recent intake of folic acid-fortified food may have distorted the serum folate levels detected. Exclusion of regular consumers of multivitamin supplements (every day or several times weekly) has a minimal effect on 2006 folate status indicators. These data indicate that the increase in folic acid-fortified foods on the Irish market largely explains high levels of folate status indicators among the subgroups examined. In addition, the data on serum folate in particular indicate that children and older adults may be more exposed to fortified foods. In the case of children for whom RCF data exist, these findings for serum folate are consistent with RCF levels.

Folic acid food fortification and the Irish experience: conclusions

The present paper shows that although voluntary food fortification can have beneficial effects on public health, it

cannot serve as a reliable public health intervention. Work undertaken by the Food Safety Authority of Ireland in preparation for mandatory fortification has found that voluntary folic acid food fortification has escalated in recent years. Preliminary findings indicate that greater intake of folic acid from such fortified foods in Ireland is a likely explanation for falling rates of pregnancies affected by NTD, but also for high blood folate status indicators, especially among children and the elderly. Recent scientific developments linking excessive folic acid intake with increased risk of colo-rectal cancer emphasise the need to ensure that individuals are not exposed to excessive folic acid levels in the food supply^(27–29).

The major disadvantage of voluntary folic acid food fortification is that it provides an uneven distribution of folic acid intake across the population (i.e. only consumers of the fortified brands of products are exposed to benefits or risks). This situation is exacerbated by complex nutrition labelling, which prevents judicious use of fortified foods to achieve targeted folic acid intake levels. Finally, given the current range of food products fortified and the variation in amounts of folic acid added between and within different brands, intake levels among consumers are hard to monitor.

These issues collectively indicate an urgent need for regulation of voluntary folic acid food fortification both in terms of amounts of folic acid added and the range of foods in which such fortification is permitted. Furthermore, nutrition labelling of fortified foods should be clear to enable consumers to achieve targeted intake levels. Such legislation is currently being developed at the European level.

Acknowledgements

The work of the Folic Acid Food Fortification Implementation Group, Food Safety Authority of Ireland is gratefully acknowledged. Particular thanks are due to Professor John M. Scott and Dr Anne M. Molloy (Trinity College Dublin, Dublin, Republic of Ireland) and Dr Sean Daly (Coombe Women's Hospital, Dublin, Republic of Ireland) who carried out the baseline monitoring investigative studies, the preliminary findings of which are highlighted in this paper. The work of Una McMenamin and Susan Gallagher, who conducted the supermarket surveys, and Christina Tlustos, who carried out the re-modelling to account for 2007 fortification levels, is gratefully appreciated. Finally, special thanks are due to Aileen Ward who prepared the manuscript.

References

1. MRC Vitamin Study Research Group (1991) Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. *Lancet* **338**, 131–137.
2. Botto LD, Lisi A, Robert-Gnansia E *et al.* (2005) International retrospective cohort study of neural tube defects in relation to folic acid recommendations: are the recommendations working? *Br Med J* **330**, 571.
3. Honein MA, Paulozzi LJ, Mathews TJ, Erickson JD & Wong LY (2001) Impact of folic acid fortification of the US food

- supply on the occurrence of neural tube defects. *JAMA* **285**, 2981–2986.
4. Liu S, West R, Randell E, Longerich L, Steel O'Connor K, Scott H, Crowley M, Lam A, Prabhakaran V & McCourt C (2004) A comprehensive evaluation of food fortification with folic acid for the primary prevention of neural tube defects. *BMC Pregnancy Childbirth* **4**, 20.
5. Persad VL, Van den Hof MC, Dube JM & Zimmer P (2002) Incidence of open neural tube defects in Nova Scotia after folic acid fortification. *Can Med Assoc J* **167**, 241–245.
6. National Committee on Folic Acid Food Fortification (2006) *Report of the National Committee on Folic Acid Food Fortification*. Dublin: Food Safety Authority of Ireland; available at http://www.fsai.ie/publications/reports/folic_acid.pdf
7. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, Conley MR, Weir DG & Scott JM (1997) Thermolabile variant of 5,10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. *Lancet* **349**, 1591–1593.
8. van der Put NMJ, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R & Blom HJ (1995) Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. *Lancet* **346**, 1070–1071.
9. Whitehead AS, Gallagher P, Mills JL, Kirke PN, Burke H, Molloy AM, Weir DG, Shields DC & Scott JM (1995) A genetic defect in 5,10 methylenetetrahydrofolate reductase in neural tube defects. *Q J Med* **88**, 763–766.
10. Kirke PN, Mills JL, Molloy AM *et al.* (2004) Impact of the MTHFR C677T polymorphism on risk of neural tube defects: case-control study. *Br Med J* **328**, 1535–1536.
11. Rosenberg IH (2005) Science-based micronutrient fortification: which nutrients, how much, and how to know? *Am J Clin Nutr* **82**, 279–280.
12. Malouf M, Grimley EJ & Areosa SA (2003) *Folic Acid With or Without Vitamin B12 for Cognition and Dementia. The Cochrane Database of Systematic Reviews 2003*, issue 4, CD004514. Chichester, West Sussex: John Wiley & Sons Ltd.
13. Selhub J, Bagley LC, Miller J & Rosenberg IH (2000) B vitamins, homocysteine, and neurocognitive function in the elderly. *Am J Clin Nutr* **71**, 614s–620s.
14. Durga J, van Boxtel MP, Schouten EG, Kok FJ, Jolles J, Katan MB & Verhoef P (2007) Effect of 3-year folic acid supplementation on cognitive function in older adults in the FACIT trial: a randomised, double blind, controlled trial. *Lancet* **369**, 208–216.
15. McMahon JA, Green TJ, Skeaff CM, Knight RG, Mann JI & Williams SM (2006) A controlled trial of homocysteine lowering and cognitive performance. *N Engl J Med* **354**, 2764–2772.
16. Morris MS, Jacques PF, Rosenberg IH & Selhub J (2007) Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. *Am J Clin Nutr* **85**, 193–200.
17. Smith AD (2007) Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12. *Am J Clin Nutr* **85**, 3–5.
18. The Heart Outcomes Prevention Evaluation (HOPE) 2 Investigators (2006) Homocysteine lowering with folic acid and B-vitamins in vascular disease. *N Engl J Med* **354**, 1567–1577.
19. Spence JD, Bang H, Chambless LE & Stampfer MJ (2005) Vitamin Intervention for Stroke Prevention Trial: An efficacy analysis. *Stroke* **36**, 2404–2409.
20. Wang X, Qin X, Demirtas H, Li J, Mao G, Huo Y, Sun N, Liu L & Xu X (2007) Efficacy of folic acid supplementation

- in stroke prevention: a meta-analysis. *Lancet* **369**, 1876–1882.
21. Clarke R, Lewington S, Sherliker P & Armitage J (2007) Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. *Curr Opin Clin Nutr Metab Care* **101**, 32–39.
 22. Smith AD, Kim YI & Refsum H (2008) Is folic acid good for everyone? *Am J Clin Nutr* **87**, 517–533.
 23. Wald DS, Wald NJ, Morris JK & Law M (2006) Folic acid, homocysteine, and cardiovascular disease: judging causality in the face of inconclusive trial evidence. *Br Med J* **333**, 1114–1117.
 24. Kim YI (2006) Does a high folate intake increase the risk of breast cancer? *Nutr Rev* **64**, 468–475.
 25. Ulrich CM (2007) Folate and cancer prevention: a closer look at a complex picture. *Am J Clin Nutr* **86**, 271–273.
 26. Ulrich CM & Potter JD (2007) Folate and cancer – timing is everything. *JAMA* **297**, 2408–2409.
 27. Cole BF, Baron JA, Sandler RS *et al.* (2007) Folic acid for the prevention of colorectal adenomas: A randomized clinical trial. *JAMA* **297**, 2351–2359.
 28. Mason JB, Dickstein A, Jacques PF, Haggarty P, Selhub J, Dallal G & Rosenberg IH (2007) A temporal association between folic acid fortification and an increase in colorectal cancer rates may be illuminating important biological principles: A hypothesis. *Cancer Epidemiol Biomarkers Prev* **16**, 1325–1329.
 29. Bayston R, Russell A, Wald NJ & Hoffbrand AV (2007) Folic acid fortification and cancer risk. *Lancet* **370**, 2004.
 30. European Food Safety Authority (2006) *Tolerable Upper Intake Levels for Vitamins and Minerals*. Parma, Italy: European Food Safety Authority.
 31. Scott JM & Weir DG (1998) Folic acid, homocysteine and one-carbon metabolism: a review of the essential biochemistry. *Cardiovasc Risk* **4**, 223–227.
 32. Laird PW (2005) Cancer epigenetics. *Hum Mol Genet* **14**, Suppl. 1, R65–R76.
 33. Davis CD & Uthus EO (2004) DNA methylation, cancer susceptibility, and nutrient interactions. *Exp Biol Med (Maywood)* **229**, 988–995.
 34. Lin J, Lee IM, Cook NR, Selhub J, Manson JE, Buring JE & Zhang SM (2008) Plasma folate, vitamin B-6, vitamin B-12, and risk of breast cancer in women. *Am J Clin Nutr* **87**, 734–743.
 35. Song J, Medline A, Mason JB, Gallinger S & Kim YI (2000) Effects of dietary folate on intestinal tumorigenesis in the ApcMin mouse. *Cancer Res* **60**, 5434–5440.
 36. Song J, Sohn KJ, Medline A, Ash C, Gallinger S & Kim YI (2000) Chemopreventive effects of dietary folate on intestinal polyps in Apc+/- Msh2-/- mice. *Cancer Res* **60**, 3191–3199.
 37. Farber S (1949) Some observations on the effect of folic acid antagonists on acute leukemia and other forms of incurable cancer. *Blood* **4**, 160–167.
 38. Heinle RW & Welch AD (1948) Experiments with pteroyl-glutamic acid deficiency in human leukaemia. *J Clin Invest* **27**, 539.
 39. Ericson U, Sonestedt E, Gullberg B, Olsson H & Wirfalt E (2007) High folate intake is associated with lower breast cancer incidence in postmenopausal women in the Malmö Diet and Cancer cohort. *Am J Clin Nutr* **86**, 434–443.
 40. Stolzenberg-Solomon RZ, Chang SC, Leitzmann MF, Johnson KA, Johnson C, Buys SS, Hoover RN & Ziegler RG (2006) Folate intake, alcohol use, and postmenopausal breast cancer risk in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. *Am J Clin Nutr* **83**, 895–904.
 41. Kelly P, McPartlin J, Goggins M, Weir DG & Scott JM (1997) Unmetabolized folic acid in serum: acute studies in subjects consuming fortified food and supplements. *Am J Clin Nutr* **65**, 1790–1795.
 42. Huang Y, Han S, Li Y, Mao Y & Xie Y (2007) Different roles of MTHFR C677T and A1298C polymorphisms in colorectal adenoma and colorectal cancer: a meta-analysis. *J Hum Genet* **52**, 73–85.
 43. Chang S-C, Lin P-C, Lin J-K, Yang S-H, Wang H-S & Li AF-Y (2007) Role of MTHFR polymorphisms and folate levels in different phenotypes of sporadic colorectal cancers. *Int J Colorectal Dis* **22**, 483–489.
 44. Hubner RA, Lubbe S, Chandler I & Houlston RS (2007) MTHFR C677T has differential influence on risk of MSI and MSS colorectal cancer. *Hum Mol Genet* **16**, 1072–1077.
 45. Food Safety Authority of Ireland (2007) *Recommendations for a National Policy on Vitamin D Supplementation for Infants in Ireland*. Dublin: Food Safety Authority of Ireland.
 46. Institute of Medicine (2006) *Dietary Reference Intakes: The Essential Guide to Nutrient Requirements*. Washington, DC: National Academies Press.
 47. McMenamin UC, Flynn MAT & Burke SJ (2008) Can fortified foods provide 400 µg folic acid daily? *Proc Nutr Soc* **67** (In the Press).
 48. Ryan YM, McPartlin J, Gibney MJ & Flynn MAT (1998) Factors affecting the erythrocyte folate status of Irish female adolescents. *Proc Nutr Soc* **57**, 147A.
 49. Daly LE, Kirke PN, Molloy A, Weir DG & Scott JM (1995) Folate levels and neural tube defects. Implications for prevention. *JAMA* **274**, 1698–1702.